Skip to content

Learn

What is the KPV peptide? The research and its FDA status

By the Everlon founding team · · How we write and review health content

Quick answer KPV is a tiny fragment, three amino acids long, of a hormone your body makes called alpha-MSH, and the research on it so far is in cells and animals, not people. In July 2026 an FDA advisory committee reviewed it as a cream or gel, and news reports say the committee recommended adding it to the list of ingredients pharmacies may compound, against the advice of FDA's own staff. KPV is still not FDA-approved and, as of October 2026, not on FDA's 503A bulks list. What changed is enforcement: in a draft policy published for public comment on October 30, 2026, HHS says it does not intend to take enforcement action against KPV compounded for topical or oral use when strict conditions are met; the draft is not final, and it is not approval.

What is KPV?

The name is the one-letter code of its three amino acids: K for lysine, P for proline and V for valine. That sequence is amino acids 11 to 13, the tail end, of alpha-melanocyte-stimulating hormone, or alpha-MSH (Getting and colleagues, 2003). FDA describes alpha-MSH as a hormone made in the pituitary gland, and KPV as a fragment of it that is also produced naturally in the body. Alpha-MSH is involved in skin coloring and other signaling.

KPV is a common name, not an official one. FDA's briefing says it found different salts and derivatives, including different active forms, sold commercially under the same name, and treats that as a patient-safety concern. Being so small makes KPV easy to make in a lab. It doesn't make it well understood in people.

What it isA natural hormone of 13 amino acidsA three-amino-acid fragment from its end (amino acids 11 to 13)
Where it is madeIn the pituitary gland, per FDAProduced naturally as a fragment, per FDA; also made in laboratories
Human studiesNot covered hereFDA's reviewers found none, by any route
Reviewed in FDA's July 2026 briefing?NoYes, for use on the skin for wounds and inflammatory conditions
On the 503A bulks list?Not on the list's current entriesNo

Research on a whole hormone doesn't automatically apply to a fragment of it. One 2003 study found the two behave differently.

What the research measured

Everything published on KPV that we could find is laboratory and animal work.

  • FDA's July 2026 review found no study in which KPV was given to people, by any route.
  • The two journal papers behind this article tested it in mice and in cultured cells, and mostly asked how it acts.
  • FDA found no toxicity studies of any kind, and no data on how the body absorbs and clears it apart from one skin test.

What each piece of work looked at:

  • Mice and macrophages. Researchers compared KPV with other alpha-MSH fragments in mice with chemically induced inflammation of the abdominal cavity (peritonitis), giving the peptides systemically, and in cultured macrophages. They concluded that KPV acts differently from the main alpha-MSH fragments and is unlikely to work through the receptors alpha-MSH uses (Getting and colleagues, 2003).
  • Human cell lines and mice. Researchers tested KPV in human intestinal cell lines and human T cells in the laboratory, and in two chemical models of colitis in mice, with KPV added to the drinking water. They proposed that a transporter called PepT1 carries it into cells (Dalmasso and colleagues, 2008).
  • The nomination FDA reviewed. It cited nine references: eight animal studies of alpha-MSH derivatives and one skin-permeation study using donated human skin. FDA's summary of that study says KPV did not pass through skin well on its own.

Neither journal paper tested KPV as a treatment in people. Full citations are in the Sources list below.

Where KPV stands with FDA

KPV is not an FDA-approved drug and, as of October 2026, is not on FDA's 503A bulks list, the list of ingredients licensed pharmacies may compound with; FDA removed it from its interim Category 2 on April 22, 2026 after the nominators withdrew their nominations, which FDA says is not a decision about the substance (how the categories work). In July 2026 FDA's reviewers proposed against adding it to the list, news reports (AJMC, July 31, 2026) say the advisory committee voted to recommend adding it anyway, and only a final rule after notice-and-comment rulemaking would change that, with no proposed rule published as of October 6, 2026 (the vote and the rulemaking path).

KPV under HHS's October 2026 draft policy

HHS, the department FDA belongs to, has drafted an enforcement-discretion policy for six peptides, KPV among them. The National Community Pharmacists Association reported it on October 29, 2026. HHS published it as a draft for comment (Federal Register, FR Doc. 2026-22192; Docket No. HHS-OASH-2026-0496; October 30, 2026), with a two-week comment period; the notice says it is "not binding on HHS or the public." The draft says HHS "does not intend to take enforcement action" against a state-licensed pharmacy, federal facility or licensed physician compounding with KPV when all of the policy's conditions are met. For KPV the routes it lists are topical and oral. A route or form the policy doesn't list isn't covered.

The conditions are the policy's seven, and all of them have to be met:

  • a valid prescription for an individual patient;
  • an ingredient from an FDA-registered manufacturer that follows current good manufacturing practice, with a certificate of analysis covering identity, purity, potency, endotoxins, heavy metals, microbial contamination and impurities;
  • KPV as the only active ingredient, with nothing combined into it;
  • the label statement "This is a compounded drug product. Not for resale.";
  • serious adverse events reported to FDA's MedWatch program;
  • for a form taken by mouth, documented human oral bioavailability;
  • no device packaged with it other than a syringe FDA has cleared through its 510(k) process.

For a form taken by mouth, the draft policy asks for documented human oral bioavailability; FDA's July 2026 review found no study of KPV given to people by any route.

As drafted, the policy would last until a final rule decides whether KPV goes on the bulks list, and HHS says it may revisit it "in whole or in part" if "a safety signal or product quality issue arises." It is not FDA approval, and it doesn't put KPV on the bulks list. The full policy and all six peptides.

A prescription vs "research use only." The policy describes compounding for a named patient on a valid prescription, from a tested ingredient made by an FDA-registered manufacturer, labeled as compounded. A "research use only" product meets none of that: no prescriber reviews your history and no pharmacy prepares it for you. The two routes are compared here.

Is this right for me?

Everlon doesn't offer this peptide. Whether any treatment suits you is a decision for a licensed provider who knows your health history, and the answer may be no.

What you can do now:

  • Hear from Everlon. The sign-up at the end of this page carries availability news, nothing else.
  • Talk to your own doctor about the skin or gut problem that brought you here. FDA's reviewers noted that approved treatments already exist for the conditions they reviewed.
  • Pass on "research use only" products. FDA has written that such a label doesn't stop a product sold for people from being treated as a drug.

However the rules change, an independent licensed provider in your state would still review your health history and decide.

How it works

  1. Enter your email below. The form at the end of this page asks for your email address and state, and nothing about your health.
  2. Hear from us only if Everlon offers it. We write about availability and nothing else, and you can unsubscribe anytime.
  3. A licensed provider still decides. Being on the list is not a reservation or a prescription. If Everlon ever offers it, a provider licensed in your state reviews your health history first and can decline.

FAQ

Is KPV FDA-approved? No. FDA's briefing says it is not a component of any FDA-approved drug.

Is KPV just alpha-MSH in a smaller form? No. It is the last three amino acids of alpha-MSH. A fragment and a full hormone are different molecules, and a 2003 mouse and cell study found they act differently.

Can a doctor prescribe KPV? HHS's draft policy would cover KPV compounded on a valid prescription for an individual patient, for topical or oral use, when every other condition is met. A prescription doesn't make it FDA-approved, and as of October 2026 KPV is still not on FDA's 503A bulks list.

Did the FDA committee approve KPV? No. An advisory committee can only recommend, and FDA's own staff proposed against adding it.

Did anything change for KPV in October 2026? For enforcement, not approval, and only in draft. HHS's draft policy, open for public comment and not final, says HHS does not intend to take enforcement action against KPV compounded under its conditions until a final rule decides its place on FDA's bulks list.

What this means for you

As of October 2026, KPV still isn't on FDA's 503A bulks list, the list of ingredients licensed pharmacies may compound with for patients, and only FDA rulemaking changes that. Until a final rule decides, HHS has proposed, in a draft policy, not to take enforcement action against KPV when its conditions are met; the draft is not final and may change. Compounded medications are not FDA-approved, and products sold online as "research use only" aren't made for people.

HHS's 2026 draft peptide compounding policy, explained covers all six peptides, and the July 2026 FDA peptide vote, explained covers what came before it.

Safety information

FDA's safety page (content current as of April 22, 2026) says, word for word: "FDA has not identified any human exposure data on drug products containing KPV administered via any route of administration. FDA lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if administered to humans."

  • Unknown risks. FDA's July 2026 briefing says the potential safety risks in humans are unknown. It could not assess the risk of immune reactions or of the peptide clumping together, because no data were available.
  • No reports is not no problems. FDA found no adverse-event reports in its main reporting database, and cautions that reporting is voluntary and compounded products are seldom reported.
  • Quality. The nomination came with no certificate of analysis, and there is no public quality testing for impurities, clumping or microbial content.
  • "Research use only" products. Websites offer KPV in oral, injectable, topical and nasal-spray forms; FDA reviewed only a cream and gel. FDA has said in writing that a "research use only" label doesn't change its view when a seller's website shows the product is meant for people. Products sold online as "research use only" are a different, unregulated market that Everlon does not participate in and that carries additional dangers.
  • If you've used it and have a reaction, tell a doctor and report it to FDA's MedWatch.

If this is a medical emergency, call 911.

Sources

  • HHS. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Appendix B; no issue or effective date printed). hhs.gov, accessed 2026-10-29
  • National Community Pharmacists Association (NCPA). Newsroom report on enforcement discretion for compounding six peptides. October 29, 2026 (news report). ncpa.org, accessed 2026-10-29
  • Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. Journal of Pharmacology and Experimental Therapeutics. 2003;306(2):631-7. PMID: 12750433. PubMed, accessed 2026-10-06 (abstract only)
  • Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-78. PMID: 18061177. PubMed, accessed 2026-10-06 (abstract only)
  • FDA. FDA Briefing Document: KPV-related bulk drug substances (KPV free base and KPV acetate). Pharmacy Compounding Advisory Committee, July 23-24, 2026. fda.gov, accessed 2026-10-06
  • FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026). fda.gov, accessed 2026-10-06
  • FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (archived copy, content current as of 09/27/2024; KPV in Category 2 from September 29, 2023). web.archive.org, accessed 2026-10-06
  • FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (interim categories list). Updated May 14, 2026. fda.gov, accessed 2026-10-06
  • FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (content current as of 05/14/2026). fda.gov, accessed 2026-10-06
  • FDA. Guidance for industry: Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act (January 2025). fda.gov, accessed 2026-10-06
  • FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov, accessed 2026-10-06
  • FDA. Warning Letters (index; the five CDER letters to online peptide sellers dated August 24, 2026, posted September 1, 2026). fda.gov, accessed 2026-10-06
  • AJMC. FDA Panel Backs 6 Peptides for Compounding. July 31, 2026 (news report). ajmc.com, accessed 2026-10-06
  • 21 CFR 216.23, Bulk drug substances that can be used to compound drug products in accordance with section 503A. ecfr.gov, accessed 2026-10-06
  • 21 U.S.C. 353a, Pharmacy compounding (2023 edition). govinfo.gov, accessed 2026-10-06

Compounded medications are prepared by a state-licensed 503A compounding pharmacy and are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are dispensed.

Individual results vary. Treatment is prescribed only when clinically appropriate, and a prescription is never guaranteed. This article is for education and is not a substitute for professional medical advice, diagnosis, or treatment. If this is a medical emergency, call 911.